Health Technology Assessment in Pharma: A Review of Major Decisions

Table 1: Types of Health Technologies, by Category
Table 2: Types of Health Technologies, by Application
Table 3: Types of Health Technologies, by Stage of Diffusion
Table 4: National Healthcare Spending in Germany, by Sector/ Services, 2015-2017
Table 5: Key Organizations Involved in the Reimbursement of Pharmaceuticals and Medical Devices in France
Table 6: Key Organizations Involved in the Reimbursement of Pharmaceuticals in the U.S.
Table 7: Public Health Insurance Programs in the U.S.
Table 8: National Healthcare Expenditures in Canada, 2010-2019
Table 9: National Healthcare Expenditures of Canada, by Sector/Service, 2017
Table 10: Trends in Japanese Healthcare Expenditures, 1995-2016
Table 11: National Healthcare Expenditures in Japan, by Sector/Service, 1995-2014
Table 12: Distribution Shares of Healthcare Spending on Pharmaceuticals in China, 2017
Table 13: Trends in the Number of Medicines Included in Previous National Essential Medicines Lists, 1982-2009
Table 14: National Health Expenditures in Australia, by Sector/Service, 2017-2018
Table 15: Key U.S. Clinical Trials on Daratumumab
Table 16: Multiple Myeloma International Staging System
Table 17: Regulatory Milestones of Daratumumab, 2013-2015
Table 18: NICE Technology Assessment of Daratumumab
Table 19: SMC Technology Assessment of Daratumumab
Table 20: HAS Technology Assessment of Daratumumab
Table 21: CADTH-pCODR Technology Assessment of Daratumumab
Table 22: Key U.S. Clinical Trials on Tildrakizumab
Table 23: Tildrakizumab Regulatory Milestones
Table 24: NICE Technology Assessment of Tildrakizumab
Table 25: SMC Technology Assessment of Tildrakizumab
Table 26: Key U.S. Clinical Trials on Tildrakizumab
Table 27: Regulatory Milestones of Durvalumab
Table 28: NICE Technology Assessment of Durvalumab
Table 29: SMC Technology Assessment of Durvalumab
Table 30: CADTH-pCODR Technology Assessment of Durvalumab
Table 31: HAS Technology Assessment of Durvalumab
Table 32: Key U.S. Clinical Trials on Abemaciclib
Table 33: Regulatory Milestones of Abemaciclib
Table 34: NICE Technology Assessment of Abemaciclib
Table 35: SMC Technology Assessment of Abemaciclib
Table 36: CADTH-pCODR Technology Assessment of Abemaciclib
Table 37: HAS Technology Assessment of Abemaciclib
Table 38: Key U.S. Clinical Trials on Ocrelizumab
Table 39: Incidence and Prevalence of Multiple Sclerosis Cases, by Country, 2016
Table 40: Regulatory Milestones of Ocrelizumab
Table 41: NICE Technology Assessment of Ocrelizumab
Table 42: SMC Technology Assessment of Ocrelizumab
Table 43: CADTH Technology Assessment of Ocrelizumab
Table 44: HAS Technology Assessment of Ocrelizumab

Figure 1: Shares of Healthcare Expenditures in the U.K., by Sector, 2017
Figure 2: IQWiG Technology Assessment Process
Figure 3: IQWiG Conclusions on the Benefits of Assessments
Figure 4: Shares of National Healthcare Expenditures in the U.S., by Sector, 2018
Figure 5: Schematic of the Reimbursement Process in the U.S.
Figure 6: Features of the Asia-Pacific Market
Figure 7: Shares of Drugs Listed in the National Formulary of China, by Therapeutic Area, 2017
Figure 8: Management of Advanced Non-small Cell Lung Cancer and Expected Outcomes